Breast cancer
Item
diagnosis of breast cancer
boolean
C0678222 (UMLS CUI [1])
Tumor stage
Item
stage i, ii, or iii disease
boolean
C1300072 (UMLS CUI [1])
Resection
Item
resected disease
boolean
C0728940 (UMLS CUI [1])
Planned treatment with anastrozole
Item
planning to undergo treatment with anastrozole at the clinically approved dose of 1 mg/day or mayo clinic cancer center rochester patient who will be enrolled on or has been enrolled on can-ncic-ma27 and has not started taking the study medication (anastrozole or exemestane)
boolean
C3641097 (UMLS CUI [1,1])
C0290883 (UMLS CUI [1,2])
hormone receptor status
Item
hormone receptor status:
boolean
C0019929 (UMLS CUI [1])
estrogen receptor-positive and/or progesterone receptor-positive primary tumor
Item
estrogen receptor-positive and/or progesterone receptor-positive primary tumor
boolean
C2919271 (UMLS CUI [1])
C2919590 (UMLS CUI [2])
Patient characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Menopausal status
Item
postmenopausal
boolean
C0025320 (UMLS CUI [1])
Questionnaire
Item
able to complete questionnaires alone or with assistance
boolean
C0034394 (UMLS CUI [1])
Prior concurrent therapy
Item
prior concurrent therapy:
boolean
C0009429 (UMLS CUI [1])
prior endocrine therapy
Item
more than 6 months since prior endocrine therapy, except tamoxifen
boolean
C0279025 (UMLS CUI [1])
Aromatase inhibitors
Item
no other prior aromatase inhibitors (e.g., letrozole or exemestane)
boolean
C0593802 (UMLS CUI [1])
Ovarian suppression
Item
no prior ovarian function suppression with surgery or radiotherapy, ovarian ablation, or luteinizing hormone-releasing hormone analogues (e.g., goserelin) as treatment for cancer
boolean
C0677922 (UMLS CUI [1])